• Explore /
  • Poster
  • / Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.

Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.

Abstract Poster

Authors

Laurence Albiges

Laurence Albiges

Gustave Roussy, Villejuif, France

Laurence Albiges , Katy Beckermann , Wilson H. Miller Jr., Jeffrey C. Goh , Pablo Gajate , Carole A. Harris , Cristina Suárez , Avivit Peer , Se Hoon Park , Walter Michael Stadler , Andrew James Weickhardt , Guy Faust , Peter C.C. Fong , Tom Waddell , Balaji Venugopal , Lina Yin , Ding Wang , Rodolfo F. Perini , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT04626518

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4553)

DOI

10.1200/JCO.2023.41.16_suppl.4553

Abstract #

4553

Poster Bd #

45

Abstract Disclosures

Similar Posters

First Author: Robert J. Motzer

First Author: Toni K. Choueiri

First Author: David F. McDermott

First Author: David F. McDermott